Bard splashes out $250m on hypothermia firm Medivance; spending cuts help Q3 growth
This article was originally published in Clinica
CR Bard is bulking up its trauma offering by agreeing to acquire Medivance, the leader in the therapeutic hypothermia market, for around $250m. Bard CEO Timothy Ring described the sector as "an emerging and growing space" that is expanding at a double-digit rate.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.